Big Market Beckons As Celsion’s China ThermaDox Plans Advance
This article was originally published in PharmAsia News
Celsion expects a regulatory clearance for Chinese sites to participate in its ongoing international Phase III trial with ThermoDox to accelerate the development of the drug in China, where the company aims to bring the doxorubicin preparation into the world’s largest liver cancer market through a manufacturing partnership with Hisun and a possible future commercial partner.
You may also be interested in...
Celsion plans to bring its first-line immune-oncology drug into clinical studies in China in 2018, with the help from its long-term local partner Zhejiang Hisun Pharmaceuticals. The partnership with Hisun serves multiple strategic purposes for lower costs and quicker approvals in the country where immunotherapeutics is becoming hot new category of cancer treatment.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.